WEBSITE BSE:532834 NSE: CAMLINFINE Inc. Year: 1993 Industry: Chemicals My Bucket: Add Stock
Last updated: 15:58
No Notes Added Yet
1. Business Overview
Camlin Fine Sciences Ltd. (CFSL) is a leading global manufacturer and supplier of specialty chemicals and ingredients, primarily catering to the food, feed, personal care, fragrance, and pharmaceutical industries. The company's core business involves the production of a range of products including antioxidants (such as TBHQ, BHA), aroma chemicals (like Vanillin, Ethyl Vanillin), performance chemicals, and nutrition ingredients. CFSL operates on a business-to-business (B2B) model, selling its manufactured products to other companies for use in their end products. The company generates revenue by leveraging its expertise in chemical synthesis, backward integration for key raw materials, and a global distribution network.
2. Key Segments / Revenue Mix
Camlin Fine Sciences operates primarily in the specialty chemicals domain, which can be broadly segmented by product type and end-use application. While specific revenue contributions by segment are not publicly detailed consistently, the key product categories include:
Antioxidants: A significant portion of their business, including products like Tertiary Butylhydroquinone (TBHQ), Butylated Hydroxyanisole (BHA), and Ascorbyl Palmitate, used in food, feed, and industrial applications for shelf-life extension and stability.
Aroma Chemicals: This segment includes Vanillin and Ethyl Vanillin, which are key flavor and fragrance ingredients used in food & beverages, personal care, and pharmaceutical industries.
Performance Chemicals & Nutrition Ingredients: This segment encompasses a range of other specialty chemicals and nutritional solutions.
The company is known to be a global leader in certain antioxidant chemistries and a prominent player in vanillin production.
3. Industry & Positioning
Camlin Fine Sciences operates in the global specialty chemicals industry, which is characterized by diverse applications, demand from multiple end-user sectors, and a focus on R&D and process innovation. The food and feed additives market, in particular, is driven by population growth, changing dietary habits, and food preservation needs. CFSL is well-positioned as a leading global producer of specific antioxidants like TBHQ and BHA, and a significant manufacturer of vanillin/ethyl vanillin. It competes with both large multinational chemical corporations and other niche specialty chemical players globally. The company differentiates itself through backward integration for key raw materials (e.g., catechol for vanillin, hydroquinone for TBHQ) and a focus on product quality and certifications required by global food and feed industries.
4. Competitive Advantage (Moat)
Backward Integration: CFSL has invested significantly in backward integration for key raw materials like Catechol and Hydroquinone. This provides cost advantages, ensures supply chain stability, reduces reliance on external suppliers, and offers better control over product quality, acting as a significant barrier to entry for new players.
Process Know-how & R&D: Expertise in complex chemical synthesis and continuous investment in R&D allow the company to develop efficient manufacturing processes and innovate new products, enhancing product differentiation and cost-effectiveness.
Customer Stickiness & Regulatory Hurdles: In B2B specialty chemicals, especially for food and feed applications, switching costs can be high due to rigorous qualification processes, lengthy approval cycles, and the need for consistent quality and regulatory compliance from suppliers. CFSL's established reputation and certifications create customer loyalty.
Scale of Operations: For its core products like TBHQ and Vanillin, CFSL operates on a significant scale, allowing for economies of scale in manufacturing and procurement.
5. Growth Drivers
Increasing Demand for Processed Food & Feed: Global population growth, urbanization, and changing lifestyles are driving the demand for processed foods, convenience foods, and feed additives, which in turn boosts the need for antioxidants and other specialty ingredients.
Expansion in Aroma Chemicals: Growth in the food & beverage, personal care, and fragrance industries globally supports the demand for aroma chemicals like Vanillin and Ethyl Vanillin.
Capacity Expansions & Debottlenecking: The company's strategic investments in expanding existing capacities and setting up new facilities are expected to cater to growing demand and increase market share.
Diversification into Value-Added Products: Focus on developing and commercializing new, high-margin, value-added products and expanding into related specialty chemical segments can drive future growth.
Global Market Penetration: Enhancing its presence in key international markets through its global distribution network.
6. Risks
Raw Material Price Volatility: The company's profitability is susceptible to fluctuations in the prices of key raw materials, many of which are crude oil derivatives or other commodity chemicals.
Intense Competition: The specialty chemicals industry is competitive, with both large global players and smaller regional manufacturers. This can lead to pricing pressures and impact market share.
Regulatory Changes: The food, feed, and pharmaceutical industries are highly regulated. Changes in food safety standards, permissible additive levels, or environmental regulations in key markets can impact product demand or increase operational costs.
Foreign Exchange Fluctuations: A significant portion of CFSL's revenues and costs are denominated in foreign currencies, making it exposed to currency exchange rate volatility.
Environmental Regulations: Stricter environmental compliance norms and increasing scrutiny of chemical manufacturing processes can lead to higher capital expenditure and operating costs.
Geopolitical Risks: Global trade tensions, supply chain disruptions, or economic slowdowns in key markets can negatively impact demand and profitability.
7. Management & Ownership
Camlin Fine Sciences is promoted by the Daftary family, who have a long history in the chemicals industry, originally associated with Camlin Ltd. The management team typically comprises experienced professionals with a strong understanding of the specialty chemicals domain and global markets. The promoter group generally holds a significant stake in the company, which is common in Indian businesses, indicating alignment of interests between promoters and shareholders.
8. Outlook
Camlin Fine Sciences is well-positioned in the growing global specialty chemicals market, particularly in food and feed additives and aroma chemicals. Its strong backward integration and focus on R&D provide a competitive edge in terms of cost efficiency and quality control. The company's ongoing capacity expansions and efforts to diversify its product portfolio into higher-value segments are positive indicators for future growth. However, the business remains susceptible to volatility in raw material prices, intense competition, and evolving regulatory landscapes, which can impact profitability. A sustained focus on operational efficiency, product innovation, and strategic market penetration will be crucial for navigating these challenges and realizing its growth potential.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹2328 Cr.
Stock P/E 47.1
P/B 2.4
Current Price ₹121.2
Book Value ₹ 50.2
Face Value 1
52W High ₹334.7
Dividend Yield 0%
52W Low ₹ 96.3
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 406 | 386 | 377 | 381 | 417 | 431 | 437 | 424 | 460 | 457 |
| Other Income | 2 | 2 | 6 | 2 | 11 | 1 | 10 | 9 | 5 | 3 |
| Total Income | 408 | 388 | 382 | 383 | 429 | 432 | 447 | 432 | 464 | 460 |
| Total Expenditure | 381 | 363 | 345 | 352 | 366 | 373 | 378 | 405 | 426 | 435 |
| Operating Profit | 27 | 25 | 37 | 31 | 63 | 59 | 69 | 28 | 38 | 25 |
| Interest | 20 | 14 | 16 | 23 | 26 | 34 | 16 | 16 | 19 | 18 |
| Depreciation | 19 | 21 | 13 | 15 | 17 | 14 | 18 | 17 | 19 | 17 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | -4 | 0 | -6 | 0 | 0 | -18 |
| Profit Before Tax | -12 | -10 | 8 | -7 | 16 | 11 | 29 | -5 | 0 | -28 |
| Provision for Tax | 9 | 5 | -12 | 11 | -26 | 7 | 8 | -0 | 6 | 0 |
| Profit After Tax | -21 | -14 | 19 | -18 | 42 | 3 | 21 | -5 | -6 | -28 |
| Adjustments | 1 | 2 | -97 | -16 | -142 | -8 | -22 | -5 | -9 | -9 |
| Profit After Adjustments | -19 | -12 | -77 | -34 | -100 | -4 | -1 | -10 | -14 | -36 |
| Adjusted Earnings Per Share | -1.1 | -0.7 | -4.5 | -2 | -5.8 | -0.2 | -0 | -0.5 | -0.8 | -1.9 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 558 | 489 | 534 | 721 | 892 | 1049 | 1187 | 1412 | 1682 | 1454 | 1667 | 1778 |
| Other Income | 8 | 4 | 16 | 13 | 14 | 3 | 11 | 37 | 6 | 44 | 14 | 27 |
| Total Income | 567 | 494 | 550 | 734 | 906 | 1053 | 1198 | 1449 | 1688 | 1498 | 1681 | 1803 |
| Total Expenditure | 474 | 398 | 503 | 706 | 819 | 914 | 1000 | 1258 | 1469 | 1313 | 1448 | 1644 |
| Operating Profit | 93 | 96 | 46 | 28 | 87 | 139 | 198 | 191 | 219 | 185 | 233 | 160 |
| Interest | 24 | 24 | 31 | 32 | 41 | 48 | 48 | 41 | 66 | 70 | 111 | 69 |
| Depreciation | 16 | 17 | 22 | 27 | 29 | 33 | 44 | 56 | 63 | 56 | 64 | 71 |
| Exceptional Income / Expenses | 0 | -5 | 0 | 0 | 0 | 0 | 0 | 0 | -10 | 0 | -10 | -24 |
| Profit Before Tax | 53 | 50 | -6 | -31 | 17 | 58 | 105 | 94 | 80 | 59 | 49 | -4 |
| Provision for Tax | -2 | 14 | -2 | -7 | 14 | 28 | 40 | 34 | 41 | 6 | 0 | 14 |
| Profit After Tax | 55 | 36 | -4 | -24 | 3 | 30 | 65 | 60 | 40 | 53 | 49 | -18 |
| Adjustments | -0 | 0 | -7 | -6 | -2 | 0 | -14 | 0 | 12 | -146 | -188 | -45 |
| Profit After Adjustments | 55 | 36 | -11 | -30 | 1 | 30 | 51 | 61 | 52 | -93 | -139 | -61 |
| Adjusted Earnings Per Share | 5.6 | 3.6 | -1.1 | -2.4 | 0 | 2.4 | 3.9 | 3.8 | 3.2 | -5.4 | -7.4 | -3.2 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 15% | 6% | 10% | 12% |
| Operating Profit CAGR | 26% | 7% | 11% | 10% |
| PAT CAGR | -8% | -7% | 10% | -1% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -39% | -10% | -6% | 2% |
| ROE Average | 6% | 6% | 9% | 10% |
| ROCE Average | 11% | 10% | 11% | 12% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 135 | 176 | 213 | 371 | 371 | 403 | 643 | 748 | 819 | 865 | 902 |
| Minority's Interest | 0 | 0 | 18 | 62 | 59 | 57 | 70 | 17 | 5 | -8 | -27 |
| Borrowings | 28 | 21 | 51 | 110 | 194 | 212 | 273 | 388 | 408 | 333 | 268 |
| Other Non-Current Liabilities | -11 | -10 | -19 | -38 | -39 | -26 | -15 | 16 | 5 | -11 | -31 |
| Total Current Liabilities | 262 | 280 | 386 | 471 | 460 | 548 | 478 | 595 | 793 | 732 | 846 |
| Total Liabilities | 413 | 468 | 648 | 977 | 1046 | 1193 | 1449 | 1764 | 2030 | 1911 | 1959 |
| Fixed Assets | 106 | 140 | 199 | 276 | 270 | 304 | 581 | 601 | 858 | 816 | 702 |
| Other Non-Current Assets | 8 | 28 | 30 | 35 | 103 | 215 | 72 | 269 | 85 | 94 | 74 |
| Total Current Assets | 299 | 300 | 419 | 666 | 672 | 675 | 795 | 891 | 1086 | 999 | 1183 |
| Total Assets | 413 | 468 | 648 | 977 | 1046 | 1193 | 1449 | 1764 | 2030 | 1911 | 1959 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 4 | 9 | 8 | 21 | 38 | 53 | 52 | 76 | 108 | 94 | 80 |
| Cash Flow from Operating Activities | 46 | 72 | -9 | -15 | -9 | 86 | 117 | 145 | 51 | 139 | 27 |
| Cash Flow from Investing Activities | -26 | -66 | -83 | -149 | -2 | -90 | -133 | -249 | -125 | -66 | -75 |
| Cash Flow from Financing Activities | -15 | -7 | 91 | 182 | 26 | 3 | 39 | 136 | 60 | -86 | 72 |
| Net Cash Inflow / Outflow | 4 | -1 | -1 | 18 | 15 | -1 | 23 | 32 | -14 | -13 | 24 |
| Closing Cash & Cash Equivalent | 9 | 8 | 21 | 38 | 53 | 52 | 76 | 108 | 94 | 80 | 104 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 5.61 | 3.62 | -1.05 | -2.39 | 0.05 | 2.44 | 3.91 | 3.78 | 3.24 | -5.41 | -7.4 |
| CEPS(Rs) | 7.26 | 5.34 | 1.64 | 0.22 | 2.58 | 5.05 | 8.4 | 7.24 | 6.36 | 6.38 | 6.03 |
| DPS(Rs) | 0.44 | 0.44 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 13.73 | 17.81 | 19.87 | 28.1 | 28.08 | 32.44 | 37.68 | 40.65 | 46.1 | 47.01 | 47.23 |
| Core EBITDA Margin(%) | 14.75 | 18.2 | 5.61 | 2.03 | 8.17 | 12.89 | 15.73 | 10.92 | 12.63 | 9.68 | 13.14 |
| EBIT Margin(%) | 13.44 | 14.77 | 4.49 | 0.15 | 6.46 | 10.09 | 12.91 | 9.54 | 8.72 | 8.84 | 9.61 |
| Pre Tax Margin(%) | 9.26 | 9.92 | -1.1 | -4.25 | 1.87 | 5.55 | 8.85 | 6.66 | 4.78 | 4.03 | 2.97 |
| PAT Margin (%) | 9.65 | 7.1 | -0.81 | -3.32 | 0.34 | 2.84 | 5.51 | 4.28 | 2.37 | 3.64 | 2.96 |
| Cash Profit Margin (%) | 12.49 | 10.49 | 3.18 | 0.37 | 3.59 | 5.97 | 9.24 | 8.24 | 6.09 | 7.52 | 6.8 |
| ROA(%) | 14.15 | 8.13 | -0.8 | -2.95 | 0.3 | 2.66 | 4.95 | 3.76 | 2.1 | 2.69 | 2.55 |
| ROE(%) | 48.31 | 23.04 | -2.29 | -8.57 | 0.86 | 7.94 | 14.61 | 10.55 | 5.71 | 6.85 | 5.83 |
| ROCE(%) | 28.5 | 22.86 | 5.46 | 0.17 | 7.32 | 12.02 | 15.25 | 11.37 | 10.38 | 8.53 | 10.59 |
| Receivable days | 68.69 | 68.37 | 73.54 | 88.44 | 84.82 | 80.39 | 80.48 | 73.72 | 65.58 | 74.03 | 67.17 |
| Inventory Days | 78.55 | 112.09 | 123.85 | 110.3 | 107.28 | 101.51 | 95.03 | 89.29 | 101.91 | 135.67 | 113.84 |
| Payable days | 139.37 | 181.39 | 121.7 | 110.68 | 131.61 | 115.68 | 103.88 | 94.24 | 117.17 | 145.31 | 150.82 |
| PER(x) | 15.39 | 23.88 | 0 | 0 | 1047.27 | 15.76 | 34.97 | 36.09 | 38.39 | 0 | 0 |
| Price/Book(x) | 6.28 | 4.85 | 4.4 | 3.54 | 1.73 | 1.19 | 3.62 | 3.35 | 2.7 | 1.85 | 3.55 |
| Dividend Yield(%) | 0.51 | 0.51 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 1.77 | 2.08 | 2.3 | 2.16 | 1.08 | 0.89 | 1.84 | 1.89 | 1.59 | 1.42 | 2.19 |
| EV/Core EBITDA(x) | 10.67 | 10.59 | 26.47 | 56.61 | 11.1 | 6.77 | 11.05 | 13.99 | 12.25 | 11.13 | 15.62 |
| Net Sales Growth(%) | 9.75 | -12.35 | 9.11 | 34.96 | 23.81 | 17.6 | 13.15 | 18.95 | 19.08 | -13.54 | 14.62 |
| EBIT Growth(%) | 28.79 | -2.87 | -67.01 | -95.62 | 6271.24 | 83.61 | 44.79 | -12.05 | 8.79 | -12.32 | 24.62 |
| PAT Growth(%) | 91.53 | -34.92 | -112.39 | -440.01 | 112.45 | 892.44 | 119.1 | -7.63 | -34.06 | 33.03 | -6.71 |
| EPS Growth(%) | 88.69 | -35.42 | -129.08 | -126.93 | 101.95 | 5152.94 | 59.86 | -3.3 | -14.19 | -266.98 | -36.75 |
| Debt/Equity(x) | 1.19 | 1.02 | 1.57 | 1.07 | 1.32 | 1.31 | 1.09 | 0.95 | 1.05 | 0.82 | 0.73 |
| Current Ratio(x) | 1.14 | 1.07 | 1.09 | 1.41 | 1.46 | 1.23 | 1.66 | 1.5 | 1.37 | 1.36 | 1.4 |
| Quick Ratio(x) | 0.62 | 0.45 | 0.57 | 0.91 | 0.84 | 0.69 | 0.99 | 0.87 | 0.65 | 0.66 | 0.78 |
| Interest Cover(x) | 3.22 | 3.05 | 0.8 | 0.03 | 1.41 | 2.22 | 3.18 | 3.3 | 2.21 | 1.84 | 1.45 |
| Total Debt/Mcap(x) | 0.19 | 0.21 | 0.36 | 0.3 | 0.76 | 1.1 | 0.3 | 0.28 | 0.39 | 0.44 | 0.2 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 48.03 | 48.03 | 48.02 | 48.02 | 48.02 | 49.1 | 49.1 | 49.08 | 48.03 | 48.03 |
| FII | 0.99 | 1.69 | 1.01 | 0.81 | 0.76 | 1.47 | 2.88 | 2.12 | 2.12 | 0.94 |
| DII | 3.75 | 4.54 | 4.88 | 4.23 | 3.38 | 3.83 | 4.14 | 5.47 | 7.76 | 7.69 |
| Public | 47.23 | 45.74 | 46.08 | 46.93 | 47.83 | 45.61 | 43.88 | 43.33 | 42.09 | 43.33 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 8.04 | 8.04 | 8.04 | 8.04 | 8.04 | 9.23 | 9.23 | 9.23 | 9.23 | 9.23 |
| FII | 0.17 | 0.28 | 0.17 | 0.14 | 0.13 | 0.28 | 0.54 | 0.4 | 0.41 | 0.18 |
| DII | 0.63 | 0.76 | 0.82 | 0.71 | 0.57 | 0.72 | 0.78 | 1.03 | 1.49 | 1.48 |
| Public | 7.91 | 7.66 | 7.72 | 7.86 | 8.01 | 8.57 | 8.25 | 8.15 | 8.08 | 8.32 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16.75 | 16.75 | 16.75 | 16.75 | 16.75 | 18.79 | 18.79 | 18.8 | 19.21 | 19.21 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.